Cargando…

Management of obsessive-compulsive disorder with fluvoxamine extended release

The pharmacodynamic properties of fluvoxamine maleate include the modulation of different populations of serotonergic, dopaminergic, and sigma receptors and/or transporters, a complex pattern of activity that may account for its efficacy in the treatment of obsessive-compulsive disorder (OCD). Never...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ordacgi, Lídia, Mendlowicz, Mauro V, Fontenelle, Leonardo F
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Expert Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699655/ https://www.ncbi.nlm.nih.gov/pubmed/19557140

Ejemplares similares

An emerging role for escitalopram in the treatment of obsessive-compulsive disorder
por: Hedges, Dawson W, et al.
Publicado: (2007)

Carbamazepine extended-release capsules in bipolar disorder
por: Weisler, Richard H
Publicado: (2006)

The management of schizophrenia: focus on extended-release quetiapine fumarate
por: Peuskens, Joseph
Publicado: (2011)

Emergence of kleptomania during treatment for obsessive compulsive disorder with fluvoxamine
por: Gupta, Parveen Rani
Publicado: (2014)

Extended-release divalproex in bipolar and other psychiatric disorders: A comprehensive review
por: Stoner, Steven C, et al.
Publicado: (2007)

Evolution of gamma knife capsulotomy for intractable obsessive-compulsive disorder
por: Miguel, Euripedes C., et al.
Publicado: (2018)

Evidence-Based Pharmacotherapy for Pediatric Obsessive-Compulsive Disorder and Chronic Tic Disorders
por: De Nadai, Alessandro S., et al.
Publicado: (2011)

Novel ensemble method for the prediction of response to fluvoxamine treatment of obsessive–compulsive disorder
por: Hasanpour, Hesam, et al.
Publicado: (2018)

Response to Fluvoxamine in the Obsessive-Compulsive Disorder Patients: Bayesian Ordinal Quantile Regression
por: Safiloo, Samad, et al.
Publicado: (2021)

Abstract: Euprolactinemic Galactorrhoea in a patient of Obsessive Compulsive Disorder on Fluvoxamine therapy.
por: Raghav, Oza, et al.
Publicado: (2022)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2008)

Fluvoxamine
por: DeVane, C Lindsay
Publicado: (2005)

Fluvoxamine induced oculogyric dystonia and manic switch in a patient with obsessive compulsive disorder
por: Tikka, Sai Krishna, et al.
Publicado: (2013)

Fluvoxamine treatment response prediction in obsessive-compulsive disorder: association rule mining approach
por: Hasanpour, Hesam, et al.
Publicado: (2019)

Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures
por: Ulloa, Carol M, et al.
Publicado: (2009)

Kraepelin’s views on obsessive neurosis: a comparison with DSM-5 criteria for obsessive-compulsive disorder
por: Steinberg, Holger, et al.
Publicado: (2017)

A Clinical Staging Model for Obsessive–Compulsive Disorder: Is It Ready for Prime Time?
por: Fontenelle, Leonardo F., et al.
Publicado: (2019)

New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children
por: Domnitei, Diana, et al.
Publicado: (2010)

Decoding moral emotions in obsessive-compulsive disorder
por: Fontenelle, Leonardo F., et al.
Publicado: (2018)

Factor structure of the Dimensional Yale-Brown Obsessive-Compulsive Scale in a large sample of adults with obsessive-compulsive disorder
por: Batistuzzo, Marcelo C., et al.
Publicado: (2021)

Oxycodone hydrochloride immediate-release analgesic for managing severe pain: abuse-deterrent formulations
por: Kibbe, AH, et al.
Publicado: (2018)

Obsessive-compulsive disorder with bipolar diathesis following isotretinoin therapy remitting upon treatment with olanzapine and fluvoxamine
por: Fornaro, Michele
Publicado: (2010)

The role of lamotrigine in the management of bipolar disorder
por: Ng, Felicity, et al.
Publicado: (2007)

Mechanisms of action of fluvoxamine for COVID-19: a historical review
por: Hashimoto, Yaeko, et al.
Publicado: (2022)

New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
por: Baune, Bernhard T
Publicado: (2008)

Recommendations for managing cutaneous disorders associated with advancing age
por: Humbert, Philippe, et al.
Publicado: (2016)

Zolpidem modified-release in insomnia
por: Kirkwood, Cynthia, et al.
Publicado: (2007)

Effect of sertraline and fluvoxamine on quality of life in patients with obsessive–compulsive disorder: A 12-week interventional study
por: Brar, Jasmine, et al.
Publicado: (2022)

Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection
por: El-Hage, Wissam, et al.
Publicado: (2010)

Lung cancer incidence and mortality with extended follow-up in the National LungScreening Trial
por: Frille, Armin, et al.
Publicado: (2020)

An MRI Study of the Metabolic and Structural Abnormalities in Obsessive-Compulsive Disorder
por: de Salles Andrade, Juliana B., et al.
Publicado: (2019)

Management of Obsessive-Compulsive Disorder
por: Seibell, Phillip J., et al.
Publicado: (2014)

Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind Randomized Clinical Trial
por: Esalatmanesh, Sophia, et al.
Publicado: (2017)

Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations
por: Fujii, Akira, et al.
Publicado: (2009)

A longitudinal evaluation of free will related cognitions in obsessive–compulsive disorder
por: Moreira-de-Oliveira, Maria E., et al.
Publicado: (2022)

Prevalence of Obsessive-Compulsive Spectrum Disorders in Obsessive-Compulsive Disorder
por: Siddiqui, Mohammad Aleem, et al.
Publicado: (2018)

Symmetry Dimension in Obsessive–Compulsive Disorder: Prevalence, Severity and Clinical Correlates
por: Vellozo, Aline P., et al.
Publicado: (2021)

Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
por: Amoaku, Winfried, et al.
Publicado: (2018)

Management of Glucocorticoid-Induced Hyperglycemia
por: Shah, Parag, et al.
Publicado: (2022)

Venlafaxine in the treatment of panic disorder
por: Katzman, Martin A, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_fjj81onbtts3230nc4h5chdpoh